Medication adherence: Factors influencing compliance with prescribed medication plans☆
Section snippets
Adherence rates
For example, although the benefits of preventing and treating chronic conditions, such as hypertension and hypercholesterolemia, are clear, many patients fail to adhere to regimens repeatedly shown to slow the progression or even reverse the disease course and prevent morbidity and mortality.1, 2 For example, in a review of information for 5590 patients who experienced a first myocardial infarction (MI), those who had less than 80% adherence to statin therapy had a more than 4-fold increase in
Barriers to adherence
Poor adherence involves patient, medication, and prescriber factors.13, 14, 15 Race, marital status, current substance abuse, low literacy, poor understanding of the need for treatment, insufficient confidence in the clinician or medication, psychological problems, low motivation to change behavior, and low socioeconomic status are prominent patient factors that have a negative impact on adherence.15, 16, 17, 18 Medication factors include complexity of dosing regimen, pill burden, side effects,
New standards to assess and improve adherence
The scope of nonadherence and the variable and often modest impact of interventions to improve adherence20 are a result, at least in part, of a lack of consensus on what determines nonadherence and the absence of generally accepted standards for corrective approaches in the various settings in which health care is delivered, including the physician's office, the pharmacy, the home.21
Historically, interventional approaches have used the biomedical model of simply providing information from an
Patient factors
A large number of patient-centered characteristics influence adherence (Table 1).22 Recently, however, the WHO has made a strong case that medication adherence is based on three pillars: patient information, motivation, and behavioral skills (Figure 1).5 Of these, motivation may be the most critical. This view is consistent with global evaluations that identify motivation and readiness to change as fundamental to long-term alteration of behavior.23 The Case Management Society of America's
Patient population factors that may influence adherence
Elderly or aging patients may be more likely than their younger counterparts to have poor adherence to therapy.26 The cognitive declines of aging may place elders at particularly high risk for errors in self-medication. In a study of 70- to 97-year-old patients discharged after a hospital admission for heart failure, 27% were noncompliant after 30 days despite having received written instructions.27 Much of this failure was attributable to poor recollection of instructions. Among 75-year-olds,
Conclusion
Poor adherence to medical therapy may account for as much as $300 billion in unnecessary health care expenses each year. Nonadherence is a complicated interplay of patient, medication, and prescriber factors, but limitations in patients' medication knowledge and willingness to change behavior may be the greatest barriers to improving adherence. It is important for case managers to evaluate knowledge, motivation, and patient factors associated with adherence. These factors should be addressed as
References (53)
Medication compliance: the search for answers continues
Clin Ther
(2001)- et al.
Adherence with statin therapy in secondary prevention of coronary heart disease in Veterans Administration male population
Am J Cardiol
(2003) - et al.
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study
Clin Ther
(2003) - et al.
Factors associated with emergency department use in asthma: acute care interventions improving chronic disease outcomes
Ann Allergy Asthma Immunol
(2003) - et al.
Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease
Clin Ther
(2000) Overcoming barriers to nonadherence in asthma treatment
J Allergy Clin Immunol
(2002)- et al.
Optimizing adherence to pharmaceutical care plans
J Am Pharm Assoc
(2000) - et al.
Medication compliance in the elderly
Med Clin North Am
(1989) - et al.
Expert Panel on Compliance. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals
Circulation
(1997) - et al.
Adherence to statin treatment and readmission of patients after myocardial infarction: a 6 year follow up study
Heart
(2002)
Adherence to long-term therapies: evidence for action
Non-adherence to antipsychotic medication regimens: associations with resource use and costs
Br J Psychiatry
Medication non-adherence and asthma treatment cost
Curr Opin Allergy Clin Immunol
Patient adherence to treatment: three decades of research: a comprehensive review
J Clin Pharm Ther
Compliance: a problem in medical management
Am Fam Physician
A “stages of change” approach to helping patients change behavior
Am Fam Physician
Special report: interventions to improve patient adherence with medications for chronic cardiovascular disorders
The crucial link between literacy and health
Ann Intern Med
Addressing the challenges of adherence
J Acquir Immune Defic Syndr
Physician behaviour and compliance
J Hypertens Suppl
Effectiveness of interventions to improve patient compliance: a meta-analysis
Med Care
Measurement, correlates, and health outcomes of medication adherence among seniors
Ann Pharmacother
The illiterate patient: screening and management
Hosp Pract
In search of how people change: applications to addictive behaviors
Am Psychol
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature
J Acquir Immune Defic Syndr
Cited by (109)
Measurement, determinants, barriers, and interventions for exercise adherence: A scoping review
2023, Journal of Bodywork and Movement TherapiesA single home visit improves adherence and reduces healthcare utilization in patients with frequent exacerbations of Severe Asthma and COPD
2021, Respiratory Medicine: XCitation Excerpt :Anxiety and depression have been shown to be prevalent in patients with chronic diseases that can significantly impacts adherence [10]. In asthma and COPD, factors that contribute to poor adherence include low socioeconomic status, low literacy, beliefs in medicine and medical team, Hispanic ethnicity, medication costs, access to care and language barriers [11–13], in addition to the familiarity and proper understanding of inhaler techniques. Many programs and offices would discharge these non-compliant patients, unfortunately leading to increase in preventable exacerbations and consequent emergency room (ER) visits.
Roles of artificial intelligence in wellness, healthy living, and healthy status sensing
2020, Artificial Intelligence in Medicine: Technical Basis and Clinical ApplicationsMaking medications stick: Improving medication adherence by highlighting the personal health costs of non-compliance
2021, Behavioural Public Policy
- ☆
Reprint line:Reprint orders: Elsevier Inc, 11830 Westline Industrial Dr., St. Louis, MO 63146-3318; phone (314) 579-2838; reprint No. YMCM 264
Editor's note: This article is the first in a three-part series discussing case management's role in promoting medication adherence. This article provides a review of the literature on medication adherence, describes the extent and importance of the nonadherence problem, and describes patient characteristics and psychosocial factors that may present barriers. Article 2 will introduce evidence-based tools that case managers can use to formally assess medication adherence and patients' knowledge and motivation to modify behaviors. Article 3 will describe a national initiative under way by the Case Management Society of America to train case managers in psychosocial behavioral change and apply adherence interventions through a set of evidence-based guidelines called CMAG-1.
- 1
Jon J. Vlasnik, PharmD, BCPS, is the senior manager for clinical applications for Pfizer, Inc., in Cranberry Township, Pa.
- 2
Sherry L. Aliotta, RN, BSN, CCM, is president and CEO of S.A. Squared, Inc., and the 2004-2005 CMSA president.
- 3
Bonnie DeLor, PharmD, BCPS, is a clinical education consultant for Pfizer.